Correlation between cerebrospinal fluid soluble platelet-derived growth factor receptor β and cognitive damage and cerebrospinal fluid core biological markers in Alzheimer′s disease
10.3760/cma.j.cn113694-20210418-00273
- VernacularTitle:阿尔茨海默病患者脑脊液可溶性血小板衍生生长因子受体β与认知损害及脑脊液生物标志物的相关性研究
- Author:
Huimin WANG
1
;
Qiqiang TANG
Author Information
1. 安徽医科大学附属省立医院神经内科，合肥 230001
- Keywords:
Alzheimer disease;
Soluble platelet-derived growth factor receptor β;
Pericyte;
Cognitive function;
Cerebrospinal fluid biomarkers
- From:
Chinese Journal of Neurology
2022;55(1):47-52
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the relationship between the concentration of soluble platelet-derived growth factor receptor β (sPDGFRβ) in the cerebrospinal fluid (CSF) of patients with Alzheimer′s disease (AD) and the degree of cognitive impairment and cerebrospinal fluid biomarkers.Methods:A total of 50 patients with AD in the Department of Neurology of Provincial Hospital Affiliated to Anhui Medical University from September 2018 to August 2020 were selected as AD group, and 33 patients with normal cognition who had no significant difference in age and gender in the same period served as control group. The neuropsychological evaluation was conducted. According to the Clinical Dementia Rating scale scores, the AD patients were divided into mild AD group and moderate to severe AD group.The clinical data and cognitive function of the three groups were compared. And the level of CSF sPDGFRβ, CSF amyloid-β (Aβ) 1-40, CSF Aβ 1-42, CSF total tau protein (T-tau), CSF phosphorylated tau protein (P-tau) were measured by enzyme linked immunosorbent assay in each group. According to whether apolipoprotein E4 (ApoE4) gene was carried, the patients with AD were divided into ApoE4 + group and ApoE4 - group. Differences among the three groups were compared and the correlation analysis was carried out. Results:The levels of sPDGFRβ in the CSF of the mild AD group [(219.301±69.711) pg/ml] and the moderate to severe AD group [(235.358±86.187) pg/ml] were significantly higher than that of the control group [(184.878±52.944) pg/ml, F=3.90, P=0.024], while there was no significant difference in the level of CSF sPDGFRβ between the ApoE4 + group [(219.493±76.745) pg/ml] and the ApoE4 - group [(222.802±81.665) pg/ml, t=-0.13, P=0.900]. And the level of sPDGFRβ in the CSF in the mild AD group was positively correlated with the level of CSF P-tau ( r=0.43, P=0.019), but not correlated with Aβ 1-42, T-tau, Mini-Mental State Examination scores or Montreal Cognitive Assessment scores, whereas no significant correlation was found in the control group and the moderate to severe AD group. Conclusions:Expression of sPDGFRβ in CSF of AD patients is increased, and may relate to P-tau. Pericyte injury may be involved in the phosphorylation of tau protein in the brain of AD patients.
